Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Su, Yin-Xia; Du, Guo-Li; Shen, Hong-Li; Wang, Wen; Bao, Jian-Ling; Aierken, Aizezijiang; Wang, Bo-Wei; Jiang, Sheng; Zhu, Jun; Gao, Xiao-Ming
• Is Part Of: Journal of international medical research. Volume 47:Issue 7(2019)
• Page Start: 3115
• Page End: 3126
• Publication Date: 2019-07
• Subjects: Aromatase -- prolactinoma -- invasion -- estrogen receptor beta -- dopamine agonists -- CYP19A1 protein -- bromocriptine -- tumor suppressor protein p53 -- post-menopause -- adenoidectomy; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060519848916
• Languages: English
• ISSNs: 0300-0605

Abstract

Objectives: To investigate the expression levels of aromatase cytochrome P450 enzyme (P450AROM) and related molecules—estrogen receptor-beta (ER-β), Ki-67, and p53—in prolactinoma tumor tissue from pre- and post-menopausal women, and to determine the associations of tumor invasiveness with expression levels of these genes. Methods: This study recruited 90 patients with prolactinoma who underwent adenoidectomy between 2012 and 2017. Information was collected regarding clinical characteristics, hormones, laboratory tests, and magnetic resonance imaging-assessed tumor invasiveness. Expression levels of P450AROM, ER-β, Ki-67, and p53 were examined by immunohistochemistry in prolactinoma tissues. Results: Increased P450AROM expression was found in invasive prolactinoma tissues in post-menopausal women, compared with its expression in non-invasive prolactinoma tissues. ER-β level was significantly higher in patients resistant to treatment with bromocriptine, a dopamine agonist. However, there were no differences in rate of resistance to treatment (8.2% vs. 3.4%) or expression levels of P450AROM, Ki-67, p53, and ER-β between pre- and post-menopausal patients. Conclusions: Our results demonstrated that increased P450AROM expression in prolactinoma of post-menopausal women was positively associated with invasiveness. Moreover, ER-β level was higher in both pre- and post-menopausal patients who were resistant to dopamine agonist treatment.